1142197-14-5|2-Bromo-5-cyclopropylpyridine| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 1142197-14-5 ] Purity: 98% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 1142197-14-5 ]

CAS No. :	1142197-14-5
Formula :	C₈H₈BrN
M.W :	198.06
SMILES Code :	BrC1=NC=C(C2CC2)C=C1
MDL No. :	MFCD11869551
InChI Key :	WCHBRVOAPMMHIR-UHFFFAOYSA-N
Pubchem ID :	45788476

Safety of [ 1142197-14-5 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 1142197-14-5 ] Show Less

Physicochemical Properties

Num. heavy atoms	10
Num. arom. heavy atoms	6
Fraction Csp3	0.38
Num. rotatable bonds	1
Num. H-bond acceptors	1.0
Num. H-bond donors	0.0
Molar Refractivity	44.4
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	12.89 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.25
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	2.79
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	2.66
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	2.22
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	3.12
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.61

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.2
Solubility	0.124 mg/ml ; 0.000626 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.72
Solubility	0.38 mg/ml ; 0.00192 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-3.48
Solubility	0.0656 mg/ml ; 0.000331 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.53 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	2.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	1.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.91

Application In Synthesis of [ 1142197-14-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1142197-14-5 ]

[ 1142197-14-5 ] Synthesis Path-Downstream 1~34

1
[ 1169563-99-8 ]
[ 1142197-14-5 ]
tert-butyl 4-(5-amino-1-(5-cyclopropylpyridin-2-yl)-1H-pyrazol-3-yl)piperidine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With caesium carbonate;copper(l) iodide; (1S,2S)-N,N'-dimethyl-1,2-diaminocyclohexane; In dimethyl sulfoxide; at 130.0℃; for 15h;Inert atmosphere; sealed tube;	A mixture of tert-butyl 4-(5-amino-lH-pyrazol-3-yl)piperidine-l-carboxylate (300 mg, 1.126 ramol), <strong>[1142197-14-5]2-bromo-5-cyclopropylpyridine</strong> (234mg, 1.183mmol), copper(I) iodide (21.45mg, 0.1 13mmol), (lS,2S)-NN2-dime ylcyclohexane-l,2-diamine (16.02 mg, 0.113 mmol), and cesium carbonate (734mg, 2.253 mmol), DMSO (3 rnL), was purged with N2 for 30 min. The mixture was heated to 130 C in a sealed tube for 15 h. The mixture was cooled to rt. and water (30 mL) was added. The mixture was extracted with EtOAc (3 x 30 mL). The combined organic extracts were dried (MgS04) and concentrated in vacuo. The residue was purified by silica gel chromatography, eiuting with a solvent gradient of 0 to 40 % EtOAc in hexanes to give the product as a white solid. 1H NMR (400 MHz, CDC13) delta 8.03 (m, 1H), 7.74 (m, 1H), 7.32 (m, 1H), 5.88 (bs, 2H), 5.26 (s, 1H), 4.10 (m, 2H), 2.79 (m, 2H), 2.67 (m, 1H), 1.88-1.79 (ra, 3H), 1.61-1.54 (m, 2H), 1.42 (s, 9H), 1.20(t, J- 7.2 Hz, 1H), 0.94 (m, 2H), 0.63 (m, 2H).

References: [1]Patent: WO2012/129258,2012,A1 .Location in patent: Page/Page column 171; 172.
[2]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 677 - 682.

2
[ 1142197-14-5 ]
(5-cyclopropylpyridin-2-yl)acetic acid [ No CAS ]

References: [1]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 156 - 161.

3
[ 1142197-14-5 ]
[ 1334783-12-8 ]

References: [1]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 156 - 161.

4
[ 1116-98-9 ]
[ 1142197-14-5 ]
tert-butyl cyano(5-methoxypyridin-2-yl)acetate [ No CAS ]

References: [1]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 156 - 161.

5
[ 1142197-14-5 ]
2-bromo-5-cyclopropyl-1-(λ1-oxidanyl)-1λ4-pyridine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
98.6%	With 3-chloro-benzenecarboperoxoic acid; In chloroform; at 20.0℃;	Step 1 : <strong>[1142197-14-5]2-bromo-5-cyclopropylpyridine</strong> -oxide (245) [0747] To a solution of <strong>[1142197-14-5]2-bromo-5-cyclopropylpyridine</strong> (2.0 g, 10.1 mmol) in CHCI3 (10 mL) was added m-CPBA (2.62 g, 15.2 mmol). The reaction was stirred at room, temperature overnight. The mixture was diluted DCM and washed with 5% aq. NaHCC solution and brine. The organic layer was dried over anhydrous NaiSCH, filtered and concentrated. The residue was purified by column chromatography on silica gel eiuted with PE/EtOAc (30: 1 to 1 : 1) to give compound 245 (2.12 g, 98.6 % yield) as a white solid. LC/MS (ESI) m/z: 214 (M+H)+
	With 3-chloro-benzenecarboperoxoic acid; In chloroform; at 50.0℃; for 4h;	To a stirred solution of (2S,4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid (125 mg, 0.54 mmole) in 8 mL of CH2Cl2, was added 1-methyl imidazole (0.11 mL, 2.5 equiv.) at 0-5 C. under nitrogen atmosphere. The reaction mixture was stirred for 10 min at 0-5 C. and then added methane sulfonyl chloride (0.05 mL, 1.2 equiv) at the same temperature. It was stirred for 1 h at 0-50 C. Then 6-methylpyridin-2-amine (58 mg, 1 equiv) was added, and stirred for 18h at room temperature. Water (15 mL) was added to the reaction mixture, layers were separated and aqueous layer was extracted with DCM (3×15 mL). The combined organic layer was washed with 1N HCl (15 mL), followed by Sat NaHCO3 (15 mL) and then with brine (10 mL). Combined organic layer was dried over Na2SO4, concentrated and purified by ISCO (silica gel, eluted by 5% MeOH in DCM gradient) to obtained 171 mg (99%) of titled compound as a clear oil.

References: [1]Patent: WO2017/35355,2017,A1 .Location in patent: Paragraph 0747.
[2]Patent: WO2017/35353,2017,A1 .Location in patent: Paragraph 1520.

6
[ 1142197-14-5 ]
6-bromo-N-(tert-butyl)-3-cyclopropylpyridin-2-amine [ No CAS ]

References: [1]Patent: WO2017/35355,2017,A1 .
[2]Patent: WO2017/35353,2017,A1 .

7
[ 1142197-14-5 ]
6-bromo-3-cyclopropylpyridin-2-ylamine [ No CAS ]

References: [1]Patent: WO2017/35355,2017,A1 .
[2]Patent: WO2017/35353,2017,A1 .

8
[ 1142197-14-5 ]
tert-butyl (1R,2S,5S)-2-((6-bromo-3-cyclopropylpyridin-2-yl)carbamoyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate [ No CAS ]

References: [1]Patent: WO2017/35355,2017,A1 .
[2]Patent: WO2017/35353,2017,A1 .

9
[ 1142197-14-5 ]
(1R,2S,5S)-N-(6-bromo-3-cyclopropylpyridin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide trifluoroacetate salt [ No CAS ]

References: [1]Patent: WO2017/35355,2017,A1 .

10
[ 893738-68-6 ]
[ 1142197-14-5 ]

Yield	Reaction Conditions	Operation in experiment
76%	With copper(ll) bromide; isopentyl nitrite; at 25.0℃; for 24h;Inert atmosphere;	General procedure: Aminopyridine (1 mmol) and corresponding Cu(II) halide (0.5 mmol) were dissolveddibromo(chloro)methane (6 mL) at 25 C under an argon atmosphere. Alkyl nitrite (1.1 mmol)was added dropwise over 5 min and reaction mixture stirred at the appropriate temperature(Table 1 and 2) until GC-MS analysis of the reaction mixture indicated full consumption the of starting material. The reaction mixture was poured into 1 N NaOH (20 mL), stirred for 1 h andextracted with CH2Cl2 (3 × 20 mL). The combined organic extracts were dried (Na2SO4) andevaporated to dryness. The crude product was purified by column chromatography on silica gel,eluting with CH2Cl2. 2-Bromo-5-cyclopropylpyridine (2a): yield 76%. Rf = 0.49. 1H NMR (400MHz, CDCl3) delta 8.17 (d, J = 2.4 Hz, 1H), 7.34 (d, J = 8.2 Hz, 1H), 7.15 (dd, J =8.2, 2.4 Hz, 1H), 1.89 - 1.82 (m, 1H), 1.10 - 0.98 (m, 2H), 0.75 - 0.64 (m,2H). 13C NMR (100 MHz, CDCl3) delta 148.6, 138.8, 138.7, 135.4, 127.5, 12.5,9.1. GC-MS: tR= 7.031 min (m/z (rel. in.)) 197 (43.52%), 199 (41.85%).

References: [1]Tetrahedron Letters,2017,vol. 58,p. 1681 - 1683.

11
[ 893738-68-6 ]
[ 110-46-3 ]
[ 1142197-14-5 ]
C₁₆H₁₇N₃ [ No CAS ]
C₁₃H₁₉N [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
80%Chromat.; 9%Chromat.; 7%Chromat.	With copper(ll) bromide; at 65.0℃; for 1h;Inert atmosphere;	General procedure: Aminopyridine (1 mmol) and corresponding Cu(II) halide (0.5 mmol) were dissolveddibromo(chloro)methane (6 mL) at 25 C under an argon atmosphere. Alkyl nitrite (1.1 mmol)was added dropwise over 5 min and reaction mixture stirred at the appropriate temperature(Table 1 and 2) until GC-MS analysis of the reaction mixture indicated full consumption the of starting material. The reaction mixture was poured into 1 N NaOH (20 mL), stirred for 1 h andextracted with CH2Cl2 (3 × 20 mL). The combined organic extracts were dried (Na2SO4) andevaporated to dryness. The crude product was purified by column chromatography on silica gel,eluting with CH2Cl2. 2-Bromo-5-cyclopropylpyridine (2a): yield 76%. Rf = 0.49. 1H NMR (400MHz, CDCl3) delta 8.17 (d, J = 2.4 Hz, 1H), 7.34 (d, J = 8.2 Hz, 1H), 7.15 (dd, J =8.2, 2.4 Hz, 1H), 1.89 - 1.82 (m, 1H), 1.10 - 0.98 (m, 2H), 0.75 - 0.64 (m,2H). 13C NMR (100 MHz, CDCl3) delta 148.6, 138.8, 138.7, 135.4, 127.5, 12.5,9.1. GC-MS: tR= 7.031 min (m/z (rel. in.)) 197 (43.52%), 199 (41.85%).

References: [1]Tetrahedron Letters,2017,vol. 58,p. 1681 - 1683.

12
[ 893738-68-6 ]
[ 110-46-3 ]
[ 1142197-14-5 ]
C₁₃H₁₉N [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
80%Chromat.; 15%Chromat.	With copper(ll) bromide; at 25.0℃; for 72h;Inert atmosphere;	General procedure: Aminopyridine (1 mmol) and corresponding Cu(II) halide (0.5 mmol) were dissolveddibromo(chloro)methane (6 mL) at 25 C under an argon atmosphere. Alkyl nitrite (1.1 mmol)was added dropwise over 5 min and reaction mixture stirred at the appropriate temperature(Table 1 and 2) until GC-MS analysis of the reaction mixture indicated full consumption the of starting material. The reaction mixture was poured into 1 N NaOH (20 mL), stirred for 1 h andextracted with CH2Cl2 (3 × 20 mL). The combined organic extracts were dried (Na2SO4) andevaporated to dryness. The crude product was purified by column chromatography on silica gel,eluting with CH2Cl2. 2-Bromo-5-cyclopropylpyridine (2a): yield 76%. Rf = 0.49. 1H NMR (400MHz, CDCl3) delta 8.17 (d, J = 2.4 Hz, 1H), 7.34 (d, J = 8.2 Hz, 1H), 7.15 (dd, J =8.2, 2.4 Hz, 1H), 1.89 - 1.82 (m, 1H), 1.10 - 0.98 (m, 2H), 0.75 - 0.64 (m,2H). 13C NMR (100 MHz, CDCl3) delta 148.6, 138.8, 138.7, 135.4, 127.5, 12.5,9.1. GC-MS: tR= 7.031 min (m/z (rel. in.)) 197 (43.52%), 199 (41.85%).

References: [1]Tetrahedron Letters,2017,vol. 58,p. 1681 - 1683.

13
[ 109-99-9 ]
[ 893738-68-6 ]
[ 1142197-14-5 ]
C₁₂H₁₆BrNO [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
45%Chromat.; 49%Chromat.	With copper(ll) bromide; isopentyl nitrite; In acetonitrile; at 25.0℃; for 3h;Inert atmosphere;	General procedure: Aminopyridine (1 mmol) and corresponding Cu(II) halide (0.5 mmol) were dissolved dibromo(chloro)methane (6 mL) at 25 C under an argon atmosphere. Alkyl nitrite (1.1 mmol)was added dropwise over 5 min and reaction mixture stirred at the appropriate temperature(Table 1 and 2) until GC-MS analysis of the reaction mixture indicated full consumption the of starting material. The reaction mixture was poured into 1 N NaOH (20 mL), stirred for 1 h and extracted with CH2Cl2 (3 × 20 mL). The combined organic extracts were dried (Na2SO4) andevaporated to dryness. The crude product was purified by column chromatography on silica gel,eluting with CH2Cl2.

References: [1]Tetrahedron Letters,2017,vol. 58,p. 1681 - 1683.

14
[ 67-56-1 ]
[ 893738-68-6 ]
[ 1063960-83-7 ]
[ 1142197-14-5 ]

Yield	Reaction Conditions	Operation in experiment
80%Chromat.; 17%Chromat.	With copper(ll) bromide; isopentyl nitrite; In acetonitrile; at 25.0℃; for 16h;Inert atmosphere;	General procedure: Aminopyridine (1 mmol) and corresponding Cu(II) halide (0.5 mmol) were dissolved dibromo(chloro)methane (6 mL) at 25 C under an argon atmosphere. Alkyl nitrite (1.1 mmol)was added dropwise over 5 min and reaction mixture stirred at the appropriate temperature(Table 1 and 2) until GC-MS analysis of the reaction mixture indicated full consumption the of starting material. The reaction mixture was poured into 1 N NaOH (20 mL), stirred for 1 h and extracted with CH2Cl2 (3 × 20 mL). The combined organic extracts were dried (Na2SO4) andevaporated to dryness. The crude product was purified by column chromatography on silica gel,eluting with CH2Cl2.

References: [1]Tetrahedron Letters,2017,vol. 58,p. 1681 - 1683.

15
[ 123-91-1 ]
[ 893738-68-6 ]
[ 1142197-14-5 ]
2-(2-(2-bromoethoxy)ethoxy)-5-cyclopropylpyridine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
42%Chromat.; 21%	With copper(ll) bromide; isopentyl nitrite; In acetonitrile; at 25.0℃; for 16h;Inert atmosphere;	General procedure: Aminopyridine (1 mmol) and corresponding Cu(II) halide (0.5 mmol) were dissolved dibromo(chloro)methane (6 mL) at 25 C under an argon atmosphere. Alkyl nitrite (1.1 mmol)was added dropwise over 5 min and reaction mixture stirred at the appropriate temperature(Table 1 and 2) until GC-MS analysis of the reaction mixture indicated full consumption the of starting material. The reaction mixture was poured into 1 N NaOH (20 mL), stirred for 1 h and extracted with CH2Cl2 (3 × 20 mL). The combined organic extracts were dried (Na2SO4) andevaporated to dryness. The crude product was purified by column chromatography on silica gel,eluting with CH2Cl2.

References: [1]Tetrahedron Letters,2017,vol. 58,p. 1681 - 1683.

16
[ 893738-68-6 ]
[ 75-05-8 ]
[ 1142197-14-5 ]
N-(5-cyclopropylpyridin-2-yl)acetamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
21%Chromat.; 58%Chromat.	With copper(ll) bromide; isopentyl nitrite; at 65.0℃; for 72h;Inert atmosphere;	General procedure: Aminopyridine (1 mmol) and corresponding Cu(II) halide (0.5 mmol) were dissolveddibromo(chloro)methane (6 mL) at 25 C under an argon atmosphere. Alkyl nitrite (1.1 mmol)was added dropwise over 5 min and reaction mixture stirred at the appropriate temperature(Table 1 and 2) until GC-MS analysis of the reaction mixture indicated full consumption the of starting material. The reaction mixture was poured into 1 N NaOH (20 mL), stirred for 1 h andextracted with CH2Cl2 (3 × 20 mL). The combined organic extracts were dried (Na2SO4) andevaporated to dryness. The crude product was purified by column chromatography on silica gel,eluting with CH2Cl2.

References: [1]Tetrahedron Letters,2017,vol. 58,p. 1681 - 1683.

17
[ 1072-97-5 ]
[ 1142197-14-5 ]

References: [1]Tetrahedron Letters,2017,vol. 58,p. 1681 - 1683.

18
[ 1072-97-5 ]
[ 1063960-83-7 ]
[ 1142197-14-5 ]

References: [1]Tetrahedron Letters,2017,vol. 58,p. 1681 - 1683.

19
[ 1072-97-5 ]
[ 1142197-14-5 ]
C₁₂H₁₆BrNO [ No CAS ]

References: [1]Tetrahedron Letters,2017,vol. 58,p. 1681 - 1683.

20
[ 1072-97-5 ]
[ 1142197-14-5 ]
2-(2-(2-bromoethoxy)ethoxy)-5-cyclopropylpyridine [ No CAS ]

References: [1]Tetrahedron Letters,2017,vol. 58,p. 1681 - 1683.

21
[ 1072-97-5 ]
[ 1142197-14-5 ]
C₁₃H₁₉N [ No CAS ]

References: [1]Tetrahedron Letters,2017,vol. 58,p. 1681 - 1683.

22
[ 1142197-14-5 ]
(2S,4S)-tert-butyl 2-((6-bromo-3-cyclopropylpyridin-2-yl)carbamoyl)-4-((dimethylamino)methyl)-4-fluoropyrrolidine-1-carboxylate [ No CAS ]